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Résumé en
anglais
Despite having a reputation of low virulence, Acinetobacter baumannii is an
emerging multidrug-resistant (MDR) pathogen responsible for community- and
hospital-acquired infections that are difficult to control and treat. Interest in this
pathogen emerged about one decade ago because of its natural MDR phenotype, its
capability of acquiring new mechanisms of resistance and the existence of
nosocomial outbreaks. Recent advances in molecular biology, including full genome
sequencing of several A. baumannii isolates, has led to the discovery of the
extraordinary plasticity of their genomes, which is linked to their great propensity to
adapt to any environment, including hospitals. In this context, as well as the
increasing antimicrobial resistance amongst A. baumannii isolates to the last-line
antibiotics carbapenems and colistin, therapeutic options are very limited or absent
in some cases of infections with pandrug-resistant bacteria. However, a large
proportion of patients may be colonised by such MDR bacteria without any sign of
infection, leading to a recurrent question for clinicians as to whether antibiotic
treatment should be given and will be effective in the presence of resistance
mechanisms. The worldwide emergence of A. baumannii strains resistant to colistin
is worrying and the increasing use of colistin to treat infections caused by MDR
bacteria will inevitably increase the recovery rate of colistin-resistant isolates in the
future. Current knowledge about A. baumannii, including biological and
epidemiological aspects as well as resistance to antibiotics and antibiotic therapy,
are reviewed in this article, in addition to therapeutic recommendations.
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